Article

Verteporfin-maker QLT to merge with Atrix

Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
Related Content
50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs
April 18th 2025

50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

BVI Medical receives 510(k) FDA clearance for glaucoma surgical system
April 17th 2025

BVI Medical receives 510(k) FDA clearance for glaucoma surgical system

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

ISO issues new standards for presbyopia-correcting IOL classification
April 17th 2025

ISO issues new standards for presbyopia-correcting IOL classification

Effect of race on visual outcomes in DME treated with ranibizumab
April 17th 2025

Effect of race on visual outcomes in DME treated with ranibizumab

© 2025 MJH Life Sciences

All rights reserved.